Brainscape's Knowledge GenomeTM

Browse over 1 million classes created by top students, professors, publishers, and experts.


See full index

PR3152 Immune and Endocrine (NUS Pharmacy) > IC11 Diabetes Mellitus Management Part 1 > Flashcards

IC11 Diabetes Mellitus Management Part 1 Flashcards

1
Q

What is diabetes?

A

Metabolic disorder characterized by insulin resistance or insufficiency or both

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is the pathogenesis of T1DM?

A

Autoimmune mediated destruction of pancreatic Beta cells due to positive antibodies resulting in insulin deficiency

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the 3 stages of T1DM and how do they differ?

A

Stage 1: Presymptomatic Normoglycemia with positive Ab

Stage 2: Presymptomatic Dysglycemia with positive Ab

Stage 3: Symptomatic New onset Hyperglycemia with positive Ab

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

What is a surrogate measure of insulin and why is it used?

A

C peptide. It is a byproduct in the synthesis of insulin. If it is absent, it suggests deficiency in insulin production.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What is the pathogenesis of Type 2 DM?

A

Progressive and gradual loss of adequate Beta cell insulin secretion due to insulin resistance

Insulin resistance results when glucose utilization is impaired and hepatic glucose output increases despite the presence of insulin.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is a characteristic of Type 2 DM in glucose and insulin levels in the blood?

A

Simultaneous elevations at early stage T2DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What are 6 main differences between T1DM and T2DM?

A
  1. Age - Young < 30 y.o. vs Old > 40 y.o.
  2. Clinical presentation - Abrupt vs Gradual
  3. Insulin production - Absent vs Normal/Abnormal
  4. Primary cause - Autoimmune mediated vs insulin resistance
  5. Physical appearance - Thin vs Overweight
  6. Ketosis - Frequent vs Uncommon
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

Signs and Symptoms of Hypoglycemia

A
  1. Hunger, Fatigue, Weakness - No energy
  2. Headache, anxious, dizzy, irritable, tremor - Affect CNS
  3. Fast Heartbeat, sweating - Macrovascular effect (CV)
  4. Impaired vision - Affect eye
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Signs and symptoms of hyperglycemia (3Ps and more)

A

Polyphagia (hungry), polyuria (frequent urination), polydipsia (extreme thirst, dry skin)

Others: Blurred vision (eye), drowsiness (CNS), reduced healing (immunity)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

4 common Parameters used to measure DM

A
  1. Fasting Blood Glucose (FBG)
  2. Random / Casual Plasma Glucose
  3. Postprandial Glucose (PPG)
  4. HbA1c
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Requirements for FBG

A

No calorie intake > 8h prior

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Requirements for random plasma glucose

A

NIL, anytime of the day

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Requirements for PPG

A

2h after meals

In clinical setting, a standardized 75g oral dose of glucose can be administered (OGTT)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

When is HbA1c used? When is it not suitable?

A

Long term glucose monitoring as it measures the average blood glucose over 3-month period

Some anemia

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

At what end of the HbA1c range are contributed by basal and postprandial glucose

A

HbA1c at the lower end (7-8%) - Postprandial

HbA1c at the higher end (9-10%) - Basal

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How frequent do you use glucometers for T1DM, T2DM and at practice setting?

A

Frequency varies
- T1DM pregnancy: 4x/day before meals/bed/3 am (Higher risk of hypoglycemia, more frequent)
- T2DM: > 3X/day for multiple injection insulin
- Non-insulin injection patients: Self-monitoring blood glucose guides success therapy
- Practice setting: Before breakfast and 2h after largest meal (2X/day)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

T2DM diagnosis requirement for sample

A

At least 2 abnormal test results from the same blood sample

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

Diagnostic criteria using measuring parameters

A

HbA1c ≤ 6% = No diabetes

HbA1c ≥ 7% = Diabetes

HbA1c 6.1-6.9% = Require further diagnostic test
- FBG ≤ 6 mmol/L OR OGTT < 7.8 mmol/L = No DM
- FBG 6.1-6.9 mmol/L OR OGTT 7.8-11 mmol/L = Pre-DM
- FBG ≥ 7 mmol/L OR OGTT ≥ 11.1 mmol/L = DM

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

Associated Risks of Insulin Resistance (2 big categories)

A

Microvascular (Nephropathy, Neuropathy, Retinopathy)

Macrovascular (Cardiovascular disease)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

What risks do antidiabetic therapy help to slow down the onset and progression? Which do not?

A

Microvascular complications

Macrovascular complications do not correlate with reduced HbA1c (U shaped relationship - Worsened CV outcomes)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

What are some complications of DM?

A
  1. Micro and macrovascular
  2. Glucose toxicity - Progression of microvascular complications
  3. Degree of glucose control - Does not reduce risk for macrovascular CV events
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

Treatment targets of DM

A

HbA1c < 7% (7-8.5%) if vulnerable
FBG 4-7 mmol/L
PPG < 10 mmol/L

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
23
Q

3 types of individualized HbA1c targets

A
  1. General < 7%
  2. Stringent 6-6.5% (Young, no significant CVD)
  3. Less stringent 7.5-8% (Elderly, comorbidites)
24
Q

6 Monitoring parameters in T2DM and frequency

A
  1. Blood pressure - Every visit
  2. Eye exam - q6mth / q1yr
  3. Foot exam - self daily / q1yr (podiatrist)
  4. Lipid panel - q3-6mth / q1yr
  5. HbA1c - q3mth / q6mth
  6. Renal function (Albuminuria) - q6mth / q1yr
25
Q

Non-pharmacological management of DM

A

Therapeutic Lifestyle Change (TLC)
1. Smoking
2. Weight loss
3. Diet
4. Exercise Moderate intensity / Muscle strengthening

26
Q

Antidiabetic Drug classes

A
  1. Metformin (Biguanides)
  2. Glipizide (Sulfonylureas)
  3. Pioglitazone (Thiazolidinediones)
  4. Acarbose (Alpha Glucosidase Inhibitor)
  5. Incretins
  6. Liraglutide (GLP-1 Receptor Antagonists)
  7. Sitagliptin, Linagliptin (DPP-4 Inhibitors)
  8. Empagliflozin (SGLT2 Inhibitors)
27
Q

Metformin MOA

A

Hepatic glucose output reduction

Peripheral/Muscle glucose uptake increase (sensitivity)

28
Q

Metformin clearance

A

Renal clearance unchanged

29
Q

Metformin max dosing

A

3g (One 1g tablet TDS)

Metformin comes in 500mg, 850mg, 1g

30
Q

Metformin ADR

A

GI, anorexia, metallic taste, vitamin B12 deficiency (anemia, peripheral neuropathy), lactic acidosis (rare but severe)

31
Q

Metformin Contraindications

A
  1. Renal impairment (Severe)
  2. Hypoxia / Hypoxemia risk (HF, sepsis, liver impaired)
  3. Alcoholism
32
Q

Metformin DDI

A
  1. Alcohol (lactic acidosis risk)
  2. Iodinated contrast material / radiologic procedure
  3. Cationic drugs (Cimetidine, digoxin) affect renal tubular transport
33
Q

Metformin use in renal insufficiency according to eGFR

A

eGFR > 60 - Monitor yearly
eGFR 45-60 - Monitor every 6 months
eGFR 30-45 - Halved max dose and do not start
eGFR < 30 - Stop

34
Q

Metformin lowers HbA1c by

A

1.5%

35
Q

Metformin benefits for place in therapy

A
  1. Negligible weight gain
  2. Low side effect incidence
  3. Positive effect of lipid profile
  4. CV event reduction (Possible)
  5. Prevent / Delay T2DM – BMI > 35 kg/m2, age < 60, women with prior gestational DM (Metformin + TLC)
  6. 1st line gestational diabetes (pregnant)
36
Q

Name the first, second and third generation sulfonylureas. Why are first generations rarely used? Why is one of the 2nd generation SU preferred?

A
  1. Tolbutamide
  2. Glipizide, Gliclazide, Glibenclamide
  3. Glimepiride

1st Gen SU has more ADR except tolbutamide

Glipizide is hepatically cleared and preferred in renal impairment

37
Q

Sulfonylurea MOA and what is required for it to work

A
  1. Acts on postprandial glucose
  2. Stimulate insulin secretion by blocking ATP-sensitive potassium channels of Beta cells
  3. Reduce hepatic glucose output
  4. Increase insulin sensitivity
  5. Needs functional beta cells
38
Q

Sulfonylurea ADR

A

Hypoglycemia, weight gain, blood dyscrasias (Rare)

39
Q

Sulfonylurea DDI

A

BB (Masks symptoms of hypoglycemia), alcohol, CYP2C9 inhibitors

40
Q

Sulfonylureas’ place in therapy (HbA1c, line of use, benefits, caution, cost)

A

HbA1c lowering by 1.5% (Need functional Beta cells)
No other extra benefits
Caution with patient having irregular meals
Cost effective at initial stages

41
Q

Thiazolidinediones include

A

Pioglitazone, Rosiglitazone

42
Q

TZD MOA

A

Peroxisome proliferator activated receptor agonist ⇒ Promote cell glucose uptake

43
Q

TZD elimination route

A

Hepatic CL

44
Q

5 TZD ADR

A

Hepatotoxic – ALT > 3X ULN / Dysfunction = Do not use
Edema, Weight gain
Fracture
Bladder cancer (Pioglitazone)
LDL elevation (Rosiglitazone)

45
Q

TZD Contraindications

A

Black Box Warning – NYHA III / IV HF, active liver disease

46
Q

TZD place in therapy (HbA1c, benefits, risks)

A

HbA1c lowering by 0.5-1.4%
Benefits Fatty Liver Disease (Obese)
Consider HF risks
Fracture risks in women

47
Q

Name of Alpha Glucosidase Inhibitors

A

Acarbose

48
Q

When is acarbose used

A

In combination with other antidiabetics when diet alone cannot manage DM

49
Q

Acarbose MOA

A

Delayed glucose absorption by competitive inhibition of the enzyme that digests complex carbohydrates (PPG reduced)

50
Q

Acarbose elimination route

A

Fecal elimination

51
Q

Acarbose dosing (initiation & uptitration)

A

Starting dose 25mg BD-TDS with meal, uptitrate 25mg/day q2-4wk to max dose 150mg/day (<60kg) / 300mg/day (>60kg)

52
Q

Acarbose ADR

A

GI flatulence and diarrhea = Discontinuation
LFT raised by acarbose when >100mg TDS

53
Q

Acarbose CI

A

Breastfeeding
GI obstruction, IBS

54
Q

Acarbose DDI

A

Adsorbents, Digestive enzyme preparations

55
Q

Acarbose place in therapy (HbA1c and others)

A

HbA1c lowering by 0.5-0.8%
PPG control
Carbohydrate rich diet (Useful)

PR3152 Immune and Endocrine (NUS Pharmacy) (10 decks)

Brainscape helps you reach your goals faster, through stronger study habits.
© 2025 Bold Learning Solutions. Terms and Conditions